Research Update

Deltex Medical Group PLC
16 September 2005



16 September 2005


            Deltex Medical Group plc ('Deltex Medical' / 'Company')

   Results of Department of Health funded clinical trial published in leading
                                medical journal


Deltex Medical Group plc, the AIM listed haemodynamic monitoring company, today
announces that the results of a Department of Health funded clinical trial,
looking at the impact of the use of the Company's CardioQ monitor in patients
undergoing surgery for bowel cancer, have been published in the British Journal
of Anaesthesia.


The trial, undertaken by consultant anaesthetist Dr Howard Wakeling in
conjunction with his surgical colleagues at Worthing Hospital, demonstrated that
using the CardioQ to optimise circulating blood volume led to a reduction in
hospital stay of one and a half days when compared to fluid management based on
current best-practice.


Dr Wakeling won first prize for this work when the results were presented in
abstract form to anaesthetists attending the Association of Anaesthetists of
Great Britain and Ireland meeting in Cardiff in September 2004.


Andy Hill, Deltex Medical's Chief Executive, commented:


'This publication further adds to the already large body of clinical evidence
that consistently demonstrates how significant clinical and economic benefits
can be derived from use of the CardioQ in the management of surgical patients.'



For further information, please contact:-


Deltex Medical Group plc
01243 774 837
Nigel Keen, Chairman
Andy Hill, Chief Executive
Ewan Phillips, Finance Director

Financial Dynamics
0207 831 3113
David Yates/John Gilbert

Notes for Editors

Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs.  This causes medical
complications including peripheral and major organ failure which can lead to
death.  Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself.  Using fluids and drugs, guided by the CardioQ, to optimise the amount
of circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.



The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.


There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-


•         validated the results of the Monitor against known standards for
measuring cardiac output, demonstrating that the technology works


•         proved that the CardioQ works in a wide range of surgical procedures


•         demonstrated that the Company's technology provides significant health
and economic benefits by helping to reduce post-operative complications and
length of hospital stays by an average of 30 to 40 per cent for a wide range of
patients.




                      This information is provided by RNS
            The company news service from the London Stock Exchange                 SEFU